Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Tetra Bio Pharma Inc TBPMQ

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.


GREY:TBPMQ - Post by User

Post by Golddetectoron Nov 05, 2021 10:23am
200 Views
Post# 34091618

Guy’s response today 👇

Guy’s response today 👇  
People love to say things with no basis for their opinions.
 
If you look at the last financial statement and MD&A, Tetra $8.5M in the bank account.  The MD&A states a focus on 2 projects only: QIXLEEF and REDUVO.  The other drugs are ready to enter clinical trials but, with a market cap oriented vision, the Board decided to park these other drugs.  The vision is that once REBORN1 and the DIN is obtained the share price should change positively.  Hence, focusing our cash and energy on those 2 projects.  The impact of this is a direct reduction of the monthly burn.  
 
The positive message to take 'home' is that the new board is sensitive to the impact raises, and an ATM, have.  The CEO and Board are aligned to drive the company to achieve those two critical milestones.  Once achieved, it will be a different company.
 
Keep in mind that the public info on Tetra also states that we are still in the 'game' for government funding. 
 
Regards
 
Guy
 
 
 
 
Guy,
Does that mean we have an alternative plan in place? Ppl suggest

People love to say things with no basis for their opinions.
 
If you look at the last financial statement and MD&A, Tetra $8.5M in the bank account.  The MD&A states a focus on 2 projects only: QIXLEEF and REDUVO.  The other drugs are ready to enter clinical trials but, with a market cap oriented vision, the Board decided to park these other drugs.  The vision is that once REBORN1 and the DIN is obtained the share price should change positively.  Hence, focusing our cash and energy on those 2 projects.  The impact of this is a direct reduction of the monthly burn.  
 
The positive message to take 'home' is that the new board is sensitive to the impact raises, and an ATM, have.  The CEO and Board are aligned to drive the company to achieve those two critical milestones.  Once achieved, it will be a different company.
 
Keep in mind that the public info on Tetra also states that we are still in the 'game' for government funding. 
 
Regards
 
Guy
 
 
 
 
Guy,
Does that mean we have an alternative plan in place? Ppl suggesting that tetra is out of money. Is this correct?

<< Previous
Bullboard Posts
Next >>